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R
etinoblastoma is a rare 
childhood cancer of the retina. 
Approximately one in 20,000 
children are affected worldwide; only 
250 to 300 new cases are reported 
in the United States each year. 
Enucleation (see Glossary) is usually 
the treatment of choice for children 
with unilateral disease. Treatment of 
children with bilateral retinoblastoma 
is more challenging, as eye and vision 
preservation become priorities. 
Historically, bilateral retinoblastoma 
was treated with a combination of laser 
therapy, cryotherapy, and radiotherapy. 
Today, patients with bilateral 
retinoblastoma ﬁ  rst receive upfront 
chemotherapy to reduce the tumor 
burden, and then undergo aggressive 
focal therapies. This approach has 
increased the rate of eye salvage and 
decreases or delays the use of radiation 
therapy. 
Unfortunately, recent advances 
in targeted chemotherapy have not 
beneﬁ  ted patients with retinoblastoma 
because our knowledge is limited 
regarding the signaling pathways 
affected following the inactivation of 
the retinoblastoma gene RB1. Also, 
retinoblastoma clinical trials take years 
to complete because so few patients 
are available. Finally, pharmaceutical 
companies have little ﬁ  nancial incentive 
to develop therapies for childhood 
cancers because pediatric patients 
represent only 1% of all patients with 
cancer. Therefore, preclinical models 
that recapitulate molecular, genetic, 
and cellular features of retinoblastoma 
are essential for identifying the most 
promising new therapies. 
For decades, St. Jude Children’s 
Research Hospital has brought together 
leading researchers and clinicians to 
tackle some of the most debilitating 
childhood diseases. This article is 
based on our recent symposium, 
“Retinoblastoma: From Bench to 
Bedside,” at which ophthalmologists, 
pediatric oncologists, and cancer 
researchers from around the world 
gathered to review the current status 
of retinoblastoma management, and 
to discuss the most effective ways to use 
the preclinical retinoblastoma models 
developed last year [1–5]. 
Landmark Studies in 
Retinoblastoma Research
After studying retinoblastoma’s pattern 
of inheritance susceptibility in families 
with a history of the disease, Alfred 
Research in Translation discusses health interventions 
in the context of translation from basic to clinical 
research, or from clinical evidence to practice.
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Figure 1. p53 Prevents Invasive, Aggressive Retinoblastoma in Mice
Rb was conditionally inactivated in retinal progenitor cells by using the Chx10-Cre transgenic 
mouse line and the RbLox allele. On a p107-deﬁ  cient genetic background, these mice develop 
retinoblastoma with a penetrance of approximately 60%. However, the disease rarely progresses 
to invasive retinoblastoma with ocular hypertrophy, and the mice rarely become moribund. 
In contrast, mice lacking both copies of p53,Rb, and p107 (Chx10-Cre;RbLox/−;p53Lox/−;p107−/−) in their 
retinal progenitor cells develop aggressive, invasive retinoblastoma. More importantly, penetrance 
is 100% as bilateral retinoblastoma with a short latency (100.3 ± 42.3 days), which is ideal for testing 
new chemotherapeutic drugs. Interestingly, mice with one copy of wild-type Rb also develop 
invasive, aggressive retinoblastoma, but with a longer latency than do 
Chx10-Cre;RbLox/−;p53Lox/−;p107−/− mice. Preliminary studies indicated that these tumors have lost 
heterozygosity at the Rb locus; thus, Chx10-Cre;RbLox/−;p53Lox/−;p107−/− mice are the only mouse model 
of retinoblastoma that recapitulates this feature of human retinoblastoma.PLoS Medicine  |  www.plosmedicine.org 0972
Knudson (Fox Chase Cancer Center) 
proposed a “two-hit” model to explain 
how a putative tumor suppressor could 
be inherited as a dominant trait that 
relied on inactivation of both alleles 
of the gene [6]. His colleagues studied 
the genetic lesions in children with 
heritable retinoblastoma and cloned 
the ﬁ  rst human tumor-suppressor gene 
RB1 [7], supporting Knudson’s two-hit 
model. These important discoveries 
generated great enthusiasm for the 
possibility of improved therapies for 
retinoblastoma, as exempliﬁ  ed in 
the statement by David Abramson 
(Memorial Sloan-Kettering Cancer 
Center) in 1986: “Within ﬁ  fteen 
years, at the outside, we’ll be able to 
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Glossary
BAC-CGH: Bacterial artiﬁ  cial 
chromosome-comparative genome 
hybridization. Large overlapping regions 
of the human and mouse genomes have 
been incorporated into bacterial artiﬁ  cial 
chromosomes. These DNA fragments 
are then spotted onto glass slides in an 
array, and can be used to hybridize two 
genomic samples labeled with different 
ﬂ  uorochromes. If a particular genomic 
region is ampliﬁ  ed or deleted in one 
sample, it will be revealed as an increase 
or decrease in the intensity of the 
ﬂ  uorescence of that sample on the array. 
This approach is useful for identifying 
genomic changes in cancer cells as they 
progress from preneoplastic lesions to 
metastatic cancer.
Chx10: Most if not all retinal progenitor 
cells express the Chx10 homeobox gene. 
Mutations in the Chx10 gene cause 
microphthalmia in both humans and 
mice, indicating that the Chx10 protein 
is an important regulator of retinal 
progenitor cell proliferation. In addition, 
Chx10 is expressed in mature bipolar 
neurons and Müller glia of the mouse and 
human retina.
Chx10-Cre;RbLox/Lox;p107−/− genetic 
background: Mice with conditional 
inactivation of Rb in retinal progenitor 
cells during retinal development. The 
p107 gene is deleted in the entire 
mouse, so the retinal cells are lacking 
both Rb and p107. These mice develop 
retinoblastoma by several months of age.
Cre transgenic lines: A variety of 
transgenic mouse lines have been 
generated that express Cre recombinase 
under the control of tissue-speciﬁ  c 
promoters. For example, the Chx10
promoter drives Cre expression in retinal 
progenitor cells, bipolar cells, and Müller 
glia.
Cre: A bacteriophage P1 protein 
that rapidly catalyzes site-speciﬁ  c 
recombination between two LoxP
sites that are made up of a 34-bp DNA 
sequence. 
Drug-efﬂ  ux transporters: Some 
chemotherapeutic drugs are substrates 
for drug-efﬂ  ux transporters that are 
expressed in the brain, and as a result, 
exhibit negligible uptake in the brain. 
If cancer cells express high levels of 
drug-efﬂ  ux transporters, there may be 
an impact on how those cells respond 
to certain classes of chemotherapeutic 
agents.
Epigenetic programs: Genetic changes 
that result in alterations in gene 
expression are  key features of many 
types of cancer. However, there are many 
examples of nongenetic changes in gene 
expression that contribute to cancer 
initiation or progression. These nongenetic 
or epigenetic changes can result from 
alterations in chromosomal structure or 
from condensation as a result of DNA 
methylation or histone organization. 
Enucleation: Surgical removal of 
the eye from its orbit. Children with 
retinoblastoma who undergo enucleation 
often receive a prosthetic eye.
Exon-speciﬁ  c knock-in mouse: A 
genetically engineered mouse strain that 
encodes a single amino acid substitution 
in a single exon of the Rb gene. As a result 
of the exon-speciﬁ  c knock-in mutation, a 
normally spliced mRNA is produced that 
encodes a full-length Rb protein with a 
single amino acid substitution.
Rb null alleles: An allele of Rb that 
is mutated and makes no functional 
protein. This is in contrast to some point-
mutant alleles of Rb that retain partial 
function.
Rb,p107 conditional knock-out mice:
The conditional allele of Rb called RbLox,
contains two small DNA sequences 
called LoxP sites, which are recognition 
elements for the Cre recombinase. When 
Cre recombinase is introduced into 
the cell, it goes into the nucleus and 
deletes the DNA between the two LoxP
sites, leading to a conditional knock-out 
tissue. There is not currently a p107Lox
allele available so to inactivate both 
Rb and p107 in the developing retina, 
RbLox/−;p107−/− mice were crossed to a 
transgenic mouse line expressing Cre 
recombinase in the developing retina. 
When Rb and p107 are knocked out in the 
developing retina, retinoblastoma forms.
Rb−/− mice: Rb knock-out mice carry a 
disrupted copy of the mouse ortholog of 
the human RB1 tumor-suppressor gene. 
Rb−/− mice die in utero around day 13.5 
of gestation due to hematopoietic and 
neural defects.
RbLox: A genetically engineered mouse 
line with two LoxP sites ﬂ  anking one or 
more critical exons of the mouse Rb gene. 
When Cre recombinase is expressed in 
cells with a RbLox allele, the DNA between 
the LoxP sites is deleted, leading to a null 
allele of Rb.
RbLox/−;p53Lox/−;p107−/− mice: These 
mice are similar to the RbLox/−;p107−/−
mice described above, except that they 
also contain a conditional allele of the 
p53 tumor suppressor. Conditional 
inactivation of Rb,p53 and p107 in the 
developing retina leads to aggressive 
invasive bilateral retinoblastoma in 100% 
of mice.
SNP chips: Single nucleotide 
polymorphisms are associated 
with particular genomic regions. 
Oligonucleotide arrays, or chips, have 
been developed that allow researchers 
to compare two DNA samples, and 
determine if there are ampliﬁ  cations or 
deletions. 
SV40 large T oncogene: A viral 
oncogene from the Simian Virus 40 
genome. Large T protein binds and 
inactivates the Rb and p53 tumor-
suppressor proteins, and leads to 
deregulated cell proliferation.
Two-photon live imaging: Standard 
laser confocal imaging is not suitable 
for many in vivo, or live, imaging 
applications because the light cannot 
penetrate deep enough into the tissue, 
and the energy of the light that is 
required may kill the cells being studied. 
Two-photon imaging combines the 
energy of two photons that are half the 
energy and twice the wavelength on 
a single cell. The overall result is that 
images can be obtained much deeper 
in the tissue because of the longer 
wavelength, and the cellular toxicity is 
reduced because of the lower energy of 
the light being used.PLoS Medicine  |  www.plosmedicine.org 0973
stop retinoblastoma before it begins. 
I’m so sure of that that I’ve already 
given the drug a name. I call it retino-
revert. We’ll be able to diagnose 
a child prenatally and start giving 
retino-revert to the mother to prevent 
retinoblastoma from growing as the 
fetus is developing” [8]. However, we 
are no closer today to identifying an 
effective targeted chemotherapy for 
retinoblastoma than we were when this 
statement was made. This slow progress 
can be attributed, in part, to the lack of 
preclinical models that recapitulate the 
disease. 
The ﬁ  rst mouse model of 
retinoblastoma was generated in 1990 
by ectopically expressing the SV40 large 
T oncogene in the developing retina 
[9]. The limitation of this model is 
that the SV40 T antigen may disrupt 
pathways that are not deregulated 
in human retinoblastoma. Thus, 
treatments that are effective in this 
model may have little clinical impact. 
In 1992, genetically engineered 
mouse strains carrying an inactivated 
Rb1 gene were generated by three 
groups [10–12]. Unlike children with 
germline RB1 mutations, Rb1 mice did 
not develop retinoblastoma. In 1998, 
chimeric mouse studies demonstrated 
that p107, a gene related to RB1, was 
involved in preventing retinal tumor 
formation in mice [13]. Although 
these studies provided important 
clues about the resistance of mice to 
retinoblastoma, chimeric mice cannot 
be used as a preclinical model because 
of considerable interanimal variability 
and low efﬁ  ciency of chimeric mouse 
generation. 
New Preclinical Models 
of Retinoblastoma
Childhood central nervous system 
(CNS) tumors arise during fetal or 
early childhood development. A 
major hurdle in the development of 
preclinical retinoblastoma models has 
been our limited knowledge about 
normal neural development. In other 
words, we have greater understanding 
of the molecular genetics of 
retinoblastoma than of the normal 
developmental neurobiology of the 
retina. Over the past ten years, Connie 
Cepko (Harvard University) and many 
others have advanced the ﬁ  eld of 
retinal development, so that we now 
have a context in which to understand 
the cancer’s biology [14,15].
Retinoblastoma research marked 
2004 as an important year. Researchers 
combined developmental neurobiology 
with cancer biology to elucidate 
retinoblastoma formation, and those 
ﬁ  ndings are now being moved directly 
into the clinic [1,5,16]. Advances were 
made in three key areas. First, the 
role of Rb protein in normal retinal 
development was elucidated. The Rb 
gene regulates two distinct processes 
in the developing mouse retina: rod 
photoreceptor development and 
progenitor cell proliferation (Schweers 
B, Donovan SL, Gray J, Zhang J, 
Martins R, et al., unpublished data) 
[5,17]. In Rb  −/− mice, p107 partially 
compensates for Rb in the latter 
process but not the former, indicating 
that the two genes have both shared 
roles and unique roles (Schweers B, 
Donovan SL, Gray J, Zhang J, Martins 
R, et al., unpublished data) [5]. This 
work is an extension of Julien Sage’s 
(Stanford University) work on p107 
compensation after Rb inactivation in 
mouse embryonic ﬁ  broblasts [18]. 
The second advance was the 
generation of a mouse carrying 
targeted deletions of Rb and p107 
in the developing retina [1,19]. By 
several weeks of age, the eyes of 
Rb,p107 conditional knock-out mice 
ﬁ  lled with immature, proliferating 
retinal cells, which gave rise to 
retinoblastoma [1]. Shortly after these 
studies were published, two other 
groups published similar ﬁ  ndings 
using Cre transgenic lines with broader 
expression patterns in the retina 
(Pax6-Cre) [3] and in the developing 
CNS (Nestin-Cre) [2]. Unfortunately, 
neither Pax6-Cre nor Nestin-Cre mice 
can be used as preclinical models 
because of low penetrance, late onset, 
and nonautonomous effects (cell 
nonautonomous effects are phenotypic 
changes that occur in the tissue or cell 
being studied as a result of a change 
in the environment, rather than loss 
of the gene of interest in the tissue or 
cell itself). The importance of the p53 
pathway in retinoblastoma was shown in 
mice with retinas lacking Rb, p107, and 
p53 [1]. These mice developed bilateral 
retinoblastoma with 100% penetrance 
and a short latency; thus, they are ideal 
for testing new chemotherapeutic 
drugs (Figure 1). Also, their mosaic 
pattern of Cre expression in Chx10-Cre 
mice is a more appropriate model of 
human retinoblastoma than Pax6-Cre or 
Nestin-Cre (discussed in [1,20]).
The third advance in retinoblastoma 
research followed the generation 
and characterization of two other 
preclinical models. This work has not 
been published but was presented at 
the symposium “Retinoblastoma: From 
Bench to Bedside”; the Dyer laboratory 
and St. Jude have made these models 
directly available to the retinoblastoma 
research community. Studies on these 
animal models were combined with 
comprehensive cell culture, molecular 
biology, and pharmacokinetic studies 
to investigate drug efﬁ  cacy for the 
treatment of retinoblastoma [16]. 
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Figure 2. A Developmentally Appropriate Orthotopic Retinoblastoma Xenograft Model 
(A) Injection of 1,000 cultured human retinoblastoma cells into the vitreal cavity of newborn rat 
eyes leads to retinoblastoma by two weeks of age. The rats do not require immunosuppression 
because they are immunonaive for the ﬁ  rst 24 hours after birth. This is an ideal model for testing 
new drugs and for studying the retinoblastoma cancer stem cell properties. 
(B) Human retinoblastoma cells have been genetically engineered to express the luciferase reporter 
gene. A two-week-old rat that received an intravitreal injection of Y79-LUC cells at birth is shown. 
Y79-LUC cells are retinoblastoma cells that express the ﬁ  reﬂ  y luciferase gene under the control of 
a constitutive promoter (see [16]). At two weeks, the rat received an intraperitoneal injection of the 
luciferase substrate (luciferin). The ﬂ  uorescence is directly proportional to the tumor volume and 
the number of cells in the tumor. By using the Xenogen imaging system, we can follow individual 
tumors as they grow and respond to chemotherapy.PLoS Medicine  |  www.plosmedicine.org 0974
Analyses of ﬁ  ve drugs and their 
combinations revealed that topotecan 
combined with carboplatin is a feasible 
alternative to the current triple-drug 
therapy (i.e., etoposide, vincristine, 
and carboplatin). These preclinical 
studies may provide useful information 
to complement the ongoing RET-
5 clinical protocol at St. Jude (C.R. 
and M.W.W.) focused on the use of 
topotecan-combination chemotherapy. 
Strengths and Limitations 
of Current Preclinical Models 
of Retinoblastoma
An orthotopic xenograft model has 
been developed for retinoblastoma, 
which relies on injecting human 
retinoblastoma cells into the eyes of 
newborn rats (Figure 2) [16]. At the 
symposium, there was great enthusiasm 
for the orthotopic xenograft model 
developed at St. Jude [16], and with 
new cell lines or primary tumors 
directly injected into the eyes of 
newborn rats, this xenograft model 
could be improved further (Figure 2). 
Enthusiasm for the clonal focal model 
involving the E1A 13S retrovirus in p53-
deﬁ  cient mice [16] was dampened by 
the use of an oncogene (Schweers B, 
Donovan SL, Gray J, Zhang J, Martins 
R, et al., unpublished data) [4,21] that 
could disrupt pathways that are not 
inactivated in human tumors. Brieﬂ  y, 
a replication-incompetent retrovirus 
expressing the E1A 13S oncogene is 
injected into the subretinal space of 
p53-deﬁ  cient newborn mice. Within 
a few weeks, these mice develop focal 
clonal retinoblastoma (Schweers B, 
Donovan SL, Gray J, Zhang J, Martins 
R, et al., unpublished data) [4,16,21]. 
The approach using Cre retrovirus 
injected in the eyes of newborn 
Rb  Lox/−;p53  Lox/−;p107  −/− mice (discussed 
in [4]) was considered at the 
symposium to be superior to that 
using the E1A oncogene; however, 
the Cre-retrovirus model relies on p53 
inactivation, which is not mutated in 
human tumors. One suggestion at the 
symposium was to identify the genetic 
lesion that disrupts the p53 pathway 
in primary human tumors, and then 
genetically engineer mice with the 
same mutation. 
Two additional concerns about the 
current models were discussed. One 
is the use of Rb null alleles. Children 
with retinoblastoma often have a 
mutated RB1 allele and a null allele. 
David Goodrich (Roswell Park Cancer 
Institute) and colleagues have created 
an exon-speciﬁ  c knock-in mouse with 
a single amino acid change found in 
human retinoblastoma (Sun H, Yanjie 
C, Zhang X, Schweers B, Dyer MA, et 
al., unpublished data). The knock-in 
allele was crossed with the 
Chx10-Cre;Rb  Lox/Lox;p107  −/− and 
Chx10-Cre;Rb  Lox/Lox;p107  –/–;p53  Lox/Lox 
genetic backgrounds. The single 
amino acid change at residue 654 
is a low-penetrance allele of RB1 
in humans; it will be interesting to 
determine if mice have a similar 
phenotype. The second concern 
is that models with two germline 
mutations do not recapitulate 
human retinoblastoma. In sporadic 
retinoblastoma, acute mutations are 
believed to occur at both RB1 loci; in 
heritable retinoblastoma, one allele 
has a germline disruption and the 
other undergoes acute inactivation. 
This concern is strengthened by 
Sage’s ﬁ  nding that the timing of Rb1 
inactivation (chronic versus acute) 
inﬂ  uences p107 compensation [18]. In 
these experiments, p107 compensation 
refers to the upregulation of p107 
gene and protein expression when 
Rb expression is lost. By combining 
the knock-in point-mutant Rb allele 
described above with Cre-expressing 
retroviruses, we can more accurately 
recapitulate human retinoblastoma. 
Another topic extensively discussed 
was the role of the p53 pathway in 
retinoblastoma. Clearly, p53 inactivation 
accelerates retinoblastoma in mice 
and leads to more aggressive, invasive 
tumors (see Figure 1) [1]. However, 
whether the p53 pathway is inactivated 
in human retinoblastoma is unknown. 
Several possible mechanisms were 
presented for the inactivation of the p53 
pathway when the p53 gene is intact, 
as in retinoblastoma. It is particularly 
important that p53 is intact because it 
may provide targets for chemotherapy. 
Comprehensive analysis of this pathway 
in retinoblastoma should be a key focus 
of future research.
Using Preclinical Data in Support 
of Clinical Trials
One of the major obstacles to testing 
new chemotherapeutic combinations 
over the past 10–12 years has been 
the lack of a preclinical model that 
faithfully recapitulates the human 
disease. We are now able to merge 
our understanding and research of 
the intraocular physiology and drug 
kinetics with the unique biology of 
retinoblastoma (both in its initiation 
and in its temporal progression) in the 
same model. Researchers are now given 
the opportunity to answer some of the 
critical questions that the new era of 
conservative management has posed. 
The preclinical models have been 
successfully used to test new drugs and 
combinations [1,16]. However, more 
is still expected from these models, 
as many relevant questions have been 
left unanswered by clinical trials. More 
information regarding new agents, 
correct combinations and schedules, 
and route of administration (systemic 
or periocular) is needed. 
It is clear that one of the major 
hurdles for future progress is 
suboptimal communication 
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Figure 3. The Eye Is a Transparent System That Permits Direct Visualization of Retinoblastoma
(A) Untreated retinoblastoma involving the macula of the left eye. The translucent cornea and lens 
allow detailed visualization. The tumor is an amelanotic, partially calciﬁ  ed mass that has broken 
through the overlying retina. Dilated arterioles inﬁ  ltrate the tumor. 
(B) The same tumor after being treated with chemotherapy. The mass has completely calciﬁ  ed, 
and the caliber of the overlying retinal vessels has diminished. A focal area of atrophied retinal 
pigmented epithelium surrounds the lesion. PLoS Medicine  |  www.plosmedicine.org 0975
between the different clinical and 
translational researchers. This hurdle 
is compounded by the fact that 
there is still substantial disagreement 
among treating physicians about the 
objectives of the treatment and the 
means (treatment regimens) to achieve 
them. A simple question such as what 
constitutes the standard of care for 
a child with bilateral retinoblastoma 
is not easy to answer. For example, 
carboplatin as a single-drug regimen 
can provide ocular salvage that is as 
good as more aggressive regimens 
that also incorporate etoposide and 
vincristine, but the efﬁ  cacy of both 
regimens depends on the stage of the 
intraocular disease and the appropriate 
use of aggressive focal treatments by an 
expert team. 
It is not surprising then that single-
drug carboplatin therapy is used by 
some institutions, while others use 
the two-drug carboplatin–vincristine 
combination, the more standard three 
drug combination that incorporates 
etoposide, or a modiﬁ  cation of the 
latter that adds cyclosporine to inhibit 
drug-efﬂ  ux transporters that might be 
involved in drug resistance. Because 
of the limited number of patients 
with retinoblastoma that are eligible 
for chemotherapy clinical trials, a 
proper comparison of those treatment 
regimens may not be possible. 
While these questions are being 
proposed, new ideas are being brought 
into the equation. For example, the 
unique anatomy and physiology of 
the eye creates an environment where 
cancer remains well contained until 
advanced stages. In this context, 
increasing the intraocular concentration 
of antineoplastic agents through 
modulation of their intraocular 
pharmacokinetics, and developing 
new methods of direct intraocular 
delivery of drugs will become priorities. 
Even more challenging are efforts to 
design drugs that treat (or prevent the 
development of) retinoblastoma in 
utero, or to generate different mouse 
models that recapitulate the different 
human RB1 mutations. Gene therapy 
is also an interesting option, but this 
therapy has its own unique challenges, 
such as spread of the virus and 
secondary toxicity to the surrounding 
normal retina. How to incorporate 
these innovations into current regimens 
will become a major challenge in the 
future. Here again, the information 
gathered in the preclinical models will 
be pivotal to the successful translation 
of these innovations into the frontline 
treatments. 
Input from clinicians and 
pharmacologists is essential for 
designing experiments that will be 
clinically relevant. Pharmocokinetics, 
side effects, dose, and schedule 
are essential considerations when 
performing preclinical studies for 
retinoblastoma. For this reason, a 
retinoblastoma working group that 
includes pharmacologists, pathologists, 
neurobiologists, ophthalmologists, 
and pediatric oncologists, such as 
the one at St. Jude is essential for 
effectively moving new treatments 
tested in the lab into clinical trials. 
Just as the 20th century saw improved 
outcomes and decreased morbidity 
for retinoblastoma, so may the 21st 
century, with targeted chemotherapy 
and new methods of drug delivery 
into the eye. In this new era of 
translational research, experts from 
several different ﬁ  elds must work 
together in the delicate process of 
identifying and resolving the challenges 
posed by this unique malignancy. Just 
as retinoblastoma has been at the 
forefront of many of the advances in 
cancer biology over the past several 
decades, retinoblastoma researchers 
are in a unique position to serve as the 
example for translational research (see 
[22]). 
Retinoblastoma Provides a Unique 
Window into Tumor Growth and 
Death
Advances in retinoblastoma treatment 
are, in part, due to the unique 
environment of the eye––a transparent 
system that permits direct visualization 
of the disease (Figure 3). A clear 
cornea, lens, and vitreous are inherent 
to successful management, e.g., 
transparency is imperative for precise 
delivery of focal therapies. Imaging 
modalities (i.e., ultrasonography, 
computed tomography, and magnetic 
resonance imaging) can be used to 
conﬁ  rm the diagnosis but not to assess 
the response to treatment. Only with 
indirect ophthalmoscopy and scleral 
depression can the entire retina be 
examined. Also, tumor recurrences 
smaller than 1 mm and early vitreous 
seeding are easily appreciated by the 
trained observer; this resolution is not 
attainable by other imaging techniques. 
Future treatment regimens will 
continue to rely on the unique 
properties of the eye; however, they 
will exploit the eye’s permeability 
rather than transparency. A substantial 
body of work has already begun to 
document the efﬁ  cacy of periocular 
chemotherapy [23,24]. The volume, 
concentration, and toxicity of agents 
are limiting current endeavors; 
however, investigators are exploring 
both new drugs and new vehicles of 
delivery to achieve efﬁ  cacious ocular 
concentrations. 
Future Directions: Targeted 
Chemotherapy
To more efﬁ  ciently target 
chemotherapy to retinoblastoma 
and move away from broad-spectrum 
agents, we need to answer three 
fundamental questions: what is the 
disease’s cell-of-origin, how does it 
expand, and what genetic events occur 
after RB1 inactivation?
Typically, the cancer cell of origin 
is inferred from the expression of 
cell type–speciﬁ  c markers or other 
morphologic features. In CNS cancers, 
marker expression is difﬁ  cult to 
interpret because the cell types are 
complex. Neurobiologists deﬁ  ne 
normal cell populations by marker 
expression, dendritic and axonal 
morphology, and location within 
the CNS. These features are often 
lost or disrupted in CNS tumor cells; 
therefore, it is difﬁ  cult to determine 
their cell of origin. The use of Cre-
expressing retroviruses and two-
photon live imaging will allow us to 
follow individual tumor clones as they 
expand beyond single-infected retinal 
progenitor cells, and help to identify 
the retinoblastoma cell of origin in 
mouse models (discussed in [4]). 
Identifying the retinoblastoma cell of 
origin is essential because different cells 
may rely on entirely different pathways 
to drive proliferation and tumor 
expansion. Veriﬁ  cation that the cell of 
origin in mouse retinoblastoma is the 
same as that in human retinoblastoma 
is essential for successful use of the 
model in screening new drugs targeted 
to deregulated pathways in that cell. 
Second, we need to determine if 
retinoblastoma expands by a cancer 
stem cell mechanism [25,26] or by 
expansion of all cells in the tumor. 
A tumor can expand from a small 
population of cancer stem cells, even 
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if it did not arise from a normal stem 
cell. This is of particular importance in 
retinoblastoma because no stem cells 
are present where tumors arise in the 
neural retina [27,28]. The xenograft 
model (see Figure 2) is ideally suited 
for determining if retinoblastoma 
expands by a stem cell mechanism. 
Human and mouse tumors could be 
fractionated, serially transplanted into 
the developing eye, and followed to 
determine which cells reconstitute 
the entire tumor. Then, by efﬁ  ciently 
targeting those cells, we could halt 
tumor progression without dramatically 
altering tumor volume. If all cells 
expand, then targeted chemotherapy 
will need to focus on halting the 
expansion of all cells in the tumor.
Third, we must identify the 
secondary genetic events that follow 
RB1 inactivation. Processes such as 
escape from apoptosis (programmed 
cell death), deregulated growth, and 
telomere maintenance (capping of 
the ends of chromosomes) occur 
in most (if not all) cancers [29], 
but not all retinoblastomas achieve 
these changes through common 
genetic mechanisms. Indeed, the 
retinoblastoma cell of origin may be a 
heterogeneous population with diverse 
epigenetic programs, which may 
hinder the identiﬁ  cation of common 
pathways for targeting chemotherapy. 
Molecular genetic analysis of primary 
human retinoblastomas and mouse 
retinoblastomas by gene expression 
microarrays, BAC-CGH, and single-
nucleotide-polymorphism (SNP) 
chips provides a good starting point. 
Information on deregulated pathways 
in retinoblastoma can then be 
exploited to target chemotherapy and, 
ultimately, to halt tumor progression 
without the side effects associated with 
broad-spectrum chemotherapy. 
Conclusion 
Developing new treatments 
for a complex disease such as 
retinoblastoma requires expertise in 
pediatric oncology, ophthalmology, 
pharmacology, and developmental 
neurobiology. The open forum at 
the “Retinoblastoma: From Bench to 
Bedside” symposium provided a unique 
opportunity for experts in each of 
these areas to discuss the best way to 
take advantage of recently developed 
preclinical models of retinoblastoma 
in order to achieve the common goal 
of saving vision in children with this 
devastating cancer. 
While there is disagreement about 
the best treatment, there was a broad 
consensus about the importance of 
preclinical models to test new therapies 
prior to clinical trials. By combining 
preclinical models with analysis of 
primary human tumors, we hope 
to move away from broad-spectrum 
chemotherapy and its associated side 
effects, and more effectively target 
the pathways that are deregulated in 
retinoblastoma.
For further information, please see 
http:⁄⁄www.stjude.org/retinoblastoma, 
http:⁄⁄www.stjude.org/dyer, and 
http:⁄⁄www.cure4kids.net.  
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